Group structure
6 companies in 4 countries
Loading…
6 companies in 4 countries
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine of every company in the group, current ones first.
1–25 of 71
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ANAPROX250MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet | Naproxen | United States | Not marketed | 1980 |
| ANAPROX DS500mg base · Tablet | Naproxen | United States | Marketed | 1980 |
| ANTALGIN 550 mg COMPRIMIDOS RECUBIERTOS CON PELICULA550 mg · Comprimido recubierto con película | Naproxen | Spain | Marketed | 1987 |
| Bondronat | Ibandronic acid | EU (EMA) | Authorised | 1996 |
| Bondronat 2 mg concentraat voor oplossing voor infusieConcentraat voor oplossing voor infusie | Ibandronic acid | Netherlands | Authorised | 1996 |
| BONDRONAT 2 mg CONCENTRADO PARA SOLUCION PARA PERFUSION2 mg · Concentrado para solución para perfusión | Ibandronic acid | Spain | Authorised | 2004 |
| BONDRONAT 50 MG COMPRIMIDOS RECUBIERTOS CON PELICULA50 mg · Comprimido recubierto con película | Ibandronic acid | Spain | Marketed | 2005 |
| Bondronat 50 mg, filmomhulde tablettenFilmomhulde tablet | Ibandronic acid | Netherlands | Authorised | 2003 |
| Bondronat 6 mg concentraat voor oplossing voor infusieConcentraat voor oplossing voor infusie | Ibandronic acid | Netherlands | Authorised | 2003 |
| BONDRONAT 6 mg CONCENTRADO PARA SOLUCION PARA PERFUSION6 mg · Concentrado para solución para perfusión | Ibandronic acid | Spain | Authorised | 2005 |
| Bonviva | Ibandronic acid | EU (EMA) | Authorised | 2004 |
| BONVIVA 150 mg, COMPRIMIDOS RECUBIERTOS CON PELICULA150 mg · Comprimido recubierto | Ibandronic acid | Spain | Authorised | 2005 |
| BONVIVA 150 mg COMPRIMIDOS RECUBIERTOS CON PELICULA150 mg · Comprimido recubierto | Ibandronic acid | Spain | Marketed | 2020 |
| BONVIVA 150 mg COMPRIMIDOS RECUBIERTOS CON PELICULA150 mg · Comprimido recubierto | Ibandronic acid | Spain | Marketed | 2005 |
| Bonviva 150 mg filmomhulde tablettenFilmomhulde tablet | Ibandronic acid | Netherlands | Authorised | 2005 |
| Bonviva 3 mg oplossing voor injectieOplossing voor injectie | Ibandronic acid | Netherlands | Authorised | 2006 |
| Dipentum 250 mg, harde capsulesCapsule, hard | Olsalazine | Netherlands | Authorised | 1988 |
| Dipentum 500 mg, tablettenTablet | Olsalazine | Netherlands | Authorised | 1991 |
| EC-NAPROSYN375mg | 500mg · Tablet, delayed release | Naproxen | United States | Marketed | 1994 |
| Frisium 10, tabletten 10 mgTablet | Clobazam | Netherlands | Authorised | 1982 |
| Frisium 20, tabletten 20 mgTablet | Clobazam | Netherlands | Authorised | 1982 |
| GHRYVELIN 60 mg granulaat voor orale suspensie in sachetGranulaat voor orale suspensie | Macimorelin | Netherlands | Authorised | 2019 |
| GHRYVELIN 60 MG GRANULADO PARA SUSPENSIÓN ORAL EN SOBRE60 mg · Granulado para suspensión oral | Macimorelin | Spain | Marketed | 2021 |
| Ghryvelin (previously Macimorelin Aeterna Zentaris) | Macimorelin | EU (EMA) | Authorised | 2019 |
| Korjuny | Catumaxomab | EU (EMA) | Authorised | 2025 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Spain | 34 | 33 | 1 | CompaniesAll medicines |
| Netherlands | 22 | 22 | 0 | CompaniesAll medicines |
| European Union (EMA) | 5 | 5 | 0 | CompaniesAll medicines |
| United States | 5 | 5 | 0 | CompaniesAll medicines |
| Croatia | 3 | 3 | 0 | CompaniesAll medicines |
| Canada | 2 | 2 | 0 | CompaniesAll medicines |
Also in the registers of Colombia, France, Italy, Serbia, Sweden, United Kingdom
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
ASIC,ASIC - Company Dataset,declared13October2026 extract,CC BY3.0 Australia,https://data.gov.au/data/dataset/asic-companies. Normalized and independently classified by Prognia;no endorsement.
Licence: Creative Commons Attribution 3.0 Australia
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia, CUM otros; source update 2026-09-16; acquired 2026-10-08.
Licence: CC BY-SA 4.0
Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia, CUM renovacion; source update 2026-09-16; acquired 2026-10-08.
Licence: CC BY-SA 4.0
Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia, CUM vigentes; source update 2026-09-16; acquired 2026-10-08.
Licence: CC BY-SA 4.0
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
BDPM / ANSM, HAS and UNCAM, CIS_MITM.txt, published 13/10/2026, acquired 2026-10-25T22:15:46.803459+00:00; exact facts retained, no endorsement.
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 2 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:48.423930+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; https://www.gov.uk/government/publications/marketing-authorisations-granted-in-2026; publication updated 7 October 2026; source PDF periods January–September 2026; original bytes acquired 18 October 2026; PDF page/table/exact-authorisation projections by Prognia under OGL v3.0.
Licence: Open Government Licence v3.0; GOV.UK Crown copyright publication and linked factual MHRA grant registers
HALMED, Baza lijekova, source export 08.10.2026., acquired 2026-10-08; factual structured adaptation; Otvorena dozvola RH, NN 67/2017.
Licence: Otvorena dozvola RH
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_A_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:41 GMT; acquired 2026-10-13T17:21:06.055244+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_H_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:40 GMT; acquired 2026-10-13T17:21:06.034935+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
ALIMS, Registar humanih lekova, source 08.10.2026 02:00, downloaded 2026-10-08, https://data.gov.rs/sr/datasets/lekovi-za-upotrebu-u-khumanoj-meditsini/; structured factual adaptation; Serbian Open Data Licence.
Licence: Serbian Open Data Licence (sodl)
Läkemedelsverket, Sweden, Förvaringstemperatur och hållbarhet, source extract 2026-10-20, acquired 2026-10-20T20:46:08.868635+00:00. Original cells retained; structured adaptation by Prognia. No regulator endorsement.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)
Läkemedelsverket, Sweden, Läkemedelsprodukter, source extract 2026-10-20, acquired 2026-10-20T20:45:53.483733+00:00. Original cells retained; structured adaptation by Prognia. No regulator endorsement.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)
Report an error or request removalCorrections from the company itself are welcome.
Keep Atnahs’s medicines accurate on Prognia, see how professionals use them and answer what they ask. A 20-minute call, in English.
Book a callWell-known pharmaceutical groups, each with all its companies.